| Ticker Symbol | Name | Issuer | Category | Market Cap | Yield | Expense Ratio | Last Price | 30 Day Change % | Description |
|---|---|---|---|---|---|---|---|---|---|
| LABD | Direxion Daily S&P Biotech Bear 3x Shares | Direxion | Passive Equity | $104,807,273 | 4.45% | 0.96% | $16.76 | 32.92% | Seek daily investment results, before fees and expenses, of 300%, or 300% of the inverse (or opposite), of the performance of the S&P Biotechnology Select Industry Index. There is no guarantee the funds will meet their stated investment objectives. |
| BIS | ProShares UltraShort Nasdaq Biotechnology | ProShares | Passive Equity | $3,343,294 | 2.40% | 0.95% | $20.91 | 11.15% | Seeks daily investment results, before fees and expenses, that correspond to two times the inverse (-2x) of the daily performance of the Nasdaq Biotechnology Index. |
| IDNA | iShares Genomics Immunology and Healthcare ETF | Blackrock | Passive Equity | $133,856,775 | 1.04% | 0.47% | $21.92 | -4.98% | Seeks to track the investment results of an index composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, immunology, and bioengineering. |
| WDNA | WisdomTree BioRevolution Fund | WisdomTree | Active Equity | $2,341,395 | 0.86% | 0.45% | $17.45 | -9.13% | The WisdomTree BioRevolution Fund seeks to track the price and yield performance, before fees and expenses, of the WisdomTree BioRevolution Index . |
| BBH | VanEck Biotech ETF | VanEck | Passive Equity | $417,009,478 | 0.45% | 0.35% | $161.70 | -5.27% | Seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS US Listed Biotech 25 Index (MVBBHTR). |
| BBC | Virtus LifeSci Biotech Clinical Trials ETF | Virtus Investment Partners | Passive Equity | $10,500,985 | 0.31% | 0.79% | $21.52 | -9.88% | The investment seeks investment results that correspond, before fees and expenses, to the price and yield performance of the LifeSci Biotechnology Clinical Trials Index. |
| IBB | iShares Biotechnology | Blackrock | Passive Equity | $7,124,535,000 | 0.32% | 0.44% | $127.58 | -6.45% | The iShares Biotechnology ETF Seeks to track the investment results of an index composed of U.S.-listed equities in the biotechnology sector. |
| PSIL | AdvisorShares Psychedelics ETF | AdvisorShares | Active Equity | $7,193,600 | 0.26% | 1.00% | $1.64 | -14.09% | PSIL is actively managed to provide exposure to the emerging global psychedelics industry. |
| SBIO | ALPS Medical Breakthroughs ETF | SS&C | Passive Equity | $107,008,200 | 0.22% | 0.50% | $29.48 | -7.90% | Seeks investment results that correspond (before fees and expenses) generally to the performance of its underlying index, the S-Network Medical Breakthroughs Index (PMBI). |
| LABU | Direxion Daily S&P Biotech Bull 3x Shares | Direxion | Passive Equity | $981,048,377 | 0.44% | 0.96% | $4.84 | -29.09% | Seeks to replicate 300% of the daily performance of its benchmark, the S&P Biotechnology Select Industry Index. |
| BIB | ProShares Ultra Nasdaq Biotechnology | ProShares | Passive Equity | $83,508,750 | 0.15% | 0.95% | $51.69 | -10.69% | Seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Nasdaq Biotechnology Index. |
| PBE | Invesco Dynamic Biotechnology & Genome ETF | Invesco | Passive Equity | $248,198,612 | 0.06% | 0.59% | $60.85 | -5.07% | Based on the Dynamic Biotech & Genome Intellidex℠ Index (Index). The Fund will normally invest at least 90% of its total assets in the securities that comprise the Index. |
| XBI | SPDR S&P Biotech ETF | State Street Global Advisors | Active Equity | $6,572,212,000 | 0.02% | 0.35% | -9.87% | Seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the S&P Biotechnology Select IndustryTM Index (the “Index”) | |
| ARKG | ARK Genomic Revolution ETF | ARK | Active Equity | $1,353,996,000 | 0.00% | 0.75% | $13.40 | -16.97% | The fund is an actively-managed exchange-traded fund that will invest under normal circumstances primarily (at least 80% of its assets) in domestic and foreign equity securities of companies across multiple sectors. |
| BBP | Virtus LifeSci Biotech Products ETF | Virtus Investment Partners | Passive Equity | $18,706,559 | 0.00% | 0.79% | $52.84 | -5.59% | Seeks investment results that correspond, before fees and expenses, to the price and yield performance of the LifeSci Biotechnology Products Index. |
| BTEC | Principal Healthcare Innovators ETF | Principal | Active Equity | $37,557,035 | 0.00% | 0.42% | $32.27 | -7.68% | Seeks to tap into the increasing demand for healthcare solutions as demographic trends have driven healthcare spending to more than double in the last 20 years.1 |
| FBT | First Trust NYSE Arca Biotechnology Index Fund | First Trust | Passive Equity | $1,100,412,792 | 0.00% | 0.55% | $153.29 | -5.22% | Exchange-traded index fund. The investment objective of the Fund is to replicate as closely as possible, before fees and expenses, the price and yield of the NYSE Arca Biotechnology Index. |
| GNOM | Global X Genomics & Biotechnology ETF | Global X | Equity | $91,200,000 | 0.00% | 0.50% | $11.05 | -12.13% | Seeks to invest in companies that potentially stand to benefit from further advances in the field of genomic science, such as companies involved in gene editing, genomic sequencing, genetic medicine/therapy, computational genomics, and biotechnology |
| HELX | Franklin Genomic Advancements E | Franklin | Active Equity | $9,117,840 | 0.00% | 0.50% | $30.14 | -7.22% | The Franklin Genomic Advancements ETF (HELX) is an actively managed fund that invests in companies that stand to benefit from advancements in genomic-based research techniques and technologies. |
| XDNA | Kelly CRISPR & Gene Editing Technology ETF | Kelly Intelligence LLC | Passive Equity | $0 | 0.00% | 0.78% | $8.20 | 0.00% | Seeks to provide total return by investing in a passively managed, concentrated portfolio of companies that engage in CRISPR & gene editing technology activities. |
| IZRL | ARK Israel Innovative Technology ETF | ARK | Active Equity | $99,858,000 | 0.00% | 0.49% | $19.09 | -6.91% | IZRL tracks an equally weighted index of Israeli companies causing advancements in the areas of genomics, health care, biotechnology, industrials, manufacturing, and IT. |
| CNCR | Range Cancer Therapeutics | Exchange Traded Concepts | Passive Equity | $18,499,134 | 0.00% | 0.79% | $12.09 | -9.57% | The Fund seeks to track the total return performance of the Range Cancer Therapeutics Index. |